Yukiko Hasuike
Overview
Explore the profile of Yukiko Hasuike including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamamura-Miyazaki N, Michigami T, Ozono K, Yamamoto K, Hasuike Y
Clin Exp Nephrol
. 2022 May;
26(10):1014-1021.
PMID: 35612637
Background: Fibroblast growth factor 23 (FGF23) levels increase as kidney function decreases and are associated with increased mortality in patients with chronic kidney disease (CKD). Inflammation has also been shown...
2.
Iwasaki T, Fujimori A, Nakanishi T, Okada S, Hanawa N, Hasuike Y, et al.
BMC Nephrol
. 2021 Apr;
22(1):124.
PMID: 33832448
Background: Decreased erythropoietin levels and impaired iron metabolism due to excessive hepcidin levels are responsible for renal anaemia in patients undergoing haemodialysis. Recently, erythroferrone (ERFE) has been identified as a...
3.
Nagasawa Y, Yamamoto R, Shinzawa M, Shoji T, Hasuike Y, Nagatoya K, et al.
Clin Exp Nephrol
. 2020 Jul;
24(10):927-934.
PMID: 32642919
Background: Steroid therapy is one of the important therapies for IgA nephropathy (IgAN), but the features of the IgAN patients who have the benefit from this therapy remained unclear. Methods:...
4.
Nanami M, Suemitsu K, Nagasawa Y, Hasuike Y, Kuragano T, Nakanishi T
Contrib Nephrol
. 2019 Apr;
198:1-11.
PMID: 30991410
Background: An arteriovenous fistula (AVF) is considered the gold standard modality of vascular access (VA) for maintenance hemodialysis (HD) because of its superior patency, few complications, provision of high quality...
5.
Mizusaki K, Hasuike Y, Kimura T, Nagasawa Y, Kuragano T, Yamada Y, et al.
Blood Purif
. 2019 Apr;
47 Suppl 2:12-18.
PMID: 30943481
Background/aims: α-Klotho is mainly expressed in the kidneys, and its soluble form can prevent vascular calcifications. Inhibition of the mammalian target of rapamycin (mTOR) upregulates Klotho. We assessed serial changes...
6.
Nagasawa Y, Hasuike Y, Kuragano T, Ishihara M
Intern Med
. 2019 Feb;
58(11):1531-1532.
PMID: 30713330
No abstract available.
7.
Kimura T, Kuragano T, Yamamoto K, Nanami M, Hasuike Y, Nakanishi T
Int J Hematol
. 2018 Sep;
109(1):59-69.
PMID: 30232784
Although the primary cause of anemia in chronic kidney disease (CKD) is lack of sufficient erythropoietin (EPO), other factors may be involved, including the deregulation of iron metabolism. To clarify...
8.
Nakanishi T, Kuragano T, Nanami M, Nagasawa Y, Hasuike Y
Free Radic Biol Med
. 2018 Jul;
133:248-253.
PMID: 29958932
Chronic kidney disease (CKD) patients have an extremely high risk of developing cardiovascular diseases (CVD) compared to the general population. Systemic inflammation associated with oxidative stress could be an important...
9.
Hasuike Y, Kakita N, Aichi M, Masachika S, Kantou M, Ikeda Takahashi S, et al.
J Vasc Surg
. 2018 Jun;
69(1):174-180.e2.
PMID: 29914835
Objective: For patients with end-stage renal disease on hemodialysis, the durability of vascular access (VA) is still far from optimal, and access survival after intervention for access failure is an...
10.
Fukao W, Hasuike Y, Yamakawa T, Toyoda K, Aichi M, Masachika S, et al.
J Ren Nutr
. 2018 Apr;
28(4):270-277.
PMID: 29703633
Objective: Iron administration affects serum levels of intact (I-) fibroblast growth factor-23 (FGF23) and its cleavage product C-terminal (C-) FGF23 in iron-deficient patients on maintenance hemodialysis (MHD). The objective of...